Regeneron Data on Squamous Cell Carcinoma Presented at ESMO, Published in NEJM

 63% combined pathologic response rate for neoadjuvant Libtayo monotherapy in stage II to IV resectable CSCC per primary analysis of a confirmatory Phase 2 trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo^® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The data, from the primary analysis of a confirmatory Phase 2 trial, were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris and concurrently published in the New England Journal of Medicine (NEJM).

https://www.biospace.com/article/releases/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-in-resectable-cutaneous-squamous-cell-carcinoma-presented-at-esmo-and-published-in-nejm/